Meiji Yasuda Asset Management Co Ltd. Invests $433,000 in Boston Scientific Corporation $BSX

Meiji Yasuda Asset Management Co Ltd. bought a new position in shares of Boston Scientific Corporation (NYSE:BSX) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 10,154 shares of the medical equipment provider’s stock, valued at approximately $433,000.

Several other institutional investors have also bought and sold shares of the stock. BlackRock Inc. acquired a new position in Boston Scientific in the second quarter valued at about $5,534,781,000. Norges Bank acquired a new stake in shares of Boston Scientific during the fourth quarter worth approximately $2,199,395,000. Bank of New York Mellon Corp acquired a new stake in shares of Boston Scientific during the second quarter worth approximately $339,031,000. Deutsche Bank AG bought a new position in shares of Boston Scientific in the second quarter valued at approximately $254,247,000. Finally, Assenagon Asset Management S.A. boosted its holdings in shares of Boston Scientific by 133.6% in the 1st quarter. Assenagon Asset Management S.A. now owns 10,057,936 shares of the medical equipment provider’s stock worth $631,135,000 after acquiring an additional 5,751,760 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Up 1.7%

Shares of BSX opened at $49.86 on Wednesday. The business’s fifty day moving average price is $46.44 and its two-hundred day moving average price is $57.14. The firm has a market capitalization of $72.26 billion, a price-to-earnings ratio of 20.19, a PEG ratio of 1.07 and a beta of 0.56. Boston Scientific Corporation has a 52 week low of $42.20 and a 52 week high of $109.50. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter in the previous year, the company posted $0.75 earnings per share. The firm’s quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, analysts predict that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific announced that its board has approved a share repurchase program on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board believes its shares are undervalued.

Insider Buying and Selling

In other news, Director Edward J. Ludwig acquired 5,000 shares of the company’s stock in a transaction on Friday, July 31st. The stock was purchased at an average cost of $45.48 per share, with a total value of $227,400.00. Following the acquisition, the director owned 30,359 shares of the company’s stock, valued at $1,380,727.32. This trade represents a 19.72% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Michael F. Mahoney bought 186,240 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were acquired at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the transaction, the chief executive officer owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 194,522 shares of company stock worth $9,385,210 over the last three months. 0.34% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts recently commented on BSX shares. Needham & Company LLC decreased their price target on Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a research report on Wednesday, July 8th. Daiwa Securities Group downgraded Boston Scientific from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. Wall Street Zen lowered Boston Scientific from a “buy” rating to a “hold” rating in a research note on Sunday, August 2nd. Argus restated a “hold” rating on shares of Boston Scientific in a report on Friday, July 31st. Finally, Royal Bank Of Canada lowered their target price on Boston Scientific from $85.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, July 30th. Twenty-four research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $71.62.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.